The Association of Public Insurance with Postpartum Contraception Preference and Provision.
LARC
Medicaid
disparities
insurance
postpartum contraception
sterilization
Journal
Open access journal of contraception
ISSN: 1179-1527
Titre abrégé: Open Access J Contracept
Pays: New Zealand
ID NLM: 101700100
Informations de publication
Date de publication:
2019
2019
Historique:
received:
16
09
2019
accepted:
07
12
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
8
1
2020
Statut:
epublish
Résumé
Prior studies have noted that public insurance status is associated with increased uptake of postpartum contraception whereas others have pointed to public insurance as a barrier to accessing highly effective forms of contraception. To assess differences in planned method and provision of postpartum contraception according to insurance type. This is a secondary analysis of a retrospective cohort study examining postpartum women delivered at a single hospital in Cleveland, Ohio from 2012-2014. Contraceptive methods were analyzed according to Tier-based effectiveness as defined by the Centers for Disease Control and Prevention. The primary outcome was postpartum contraception method preference. Additional outcomes included method provision, postpartum visit attendance, and subsequent pregnancy within 365 days of delivery. Of the 8281 patients in the study cohort, 1372 (16.6%) were privately and 6990 (83.4%) were publicly insured. After adjusting for the potentially confounding clinical and demographic factors through propensity score analysis, public insurance was not associated with preference for a Tier 1 versus Tier 2 postpartum contraceptive method (matched adjusted odds ratio [maOR] 0.89, 95% CI 0.69-1.15), but was associated with a preference for Tier 1/2 vs Tier 3/None (maOR 1.41, 95% CI 1.17-1.69). There was no difference between women with private or public insurance in terms of method provision by 90 days after delivery (maOR 0.94, 95% CI 0.75-1.17). Public insurance status was also associated with decreased postpartum visit attendance (maOR 0.54, 95% CI 0.43-0.68) and increased rates of subsequent pregnancy within 365 days of delivery (maOR 1.29, 95% CI 1.05-1.59). Public insurance status does not serve as a barrier to either the preference or provision of effective postpartum contraception. Women desiring highly- or moderately effective methods of contraception should have these methods provided prior to hospital discharge to minimize barriers to method provision.
Sections du résumé
BACKGROUND
BACKGROUND
Prior studies have noted that public insurance status is associated with increased uptake of postpartum contraception whereas others have pointed to public insurance as a barrier to accessing highly effective forms of contraception.
OBJECTIVE
OBJECTIVE
To assess differences in planned method and provision of postpartum contraception according to insurance type.
STUDY DESIGN
METHODS
This is a secondary analysis of a retrospective cohort study examining postpartum women delivered at a single hospital in Cleveland, Ohio from 2012-2014. Contraceptive methods were analyzed according to Tier-based effectiveness as defined by the Centers for Disease Control and Prevention. The primary outcome was postpartum contraception method preference. Additional outcomes included method provision, postpartum visit attendance, and subsequent pregnancy within 365 days of delivery.
RESULTS
RESULTS
Of the 8281 patients in the study cohort, 1372 (16.6%) were privately and 6990 (83.4%) were publicly insured. After adjusting for the potentially confounding clinical and demographic factors through propensity score analysis, public insurance was not associated with preference for a Tier 1 versus Tier 2 postpartum contraceptive method (matched adjusted odds ratio [maOR] 0.89, 95% CI 0.69-1.15), but was associated with a preference for Tier 1/2 vs Tier 3/None (maOR 1.41, 95% CI 1.17-1.69). There was no difference between women with private or public insurance in terms of method provision by 90 days after delivery (maOR 0.94, 95% CI 0.75-1.17). Public insurance status was also associated with decreased postpartum visit attendance (maOR 0.54, 95% CI 0.43-0.68) and increased rates of subsequent pregnancy within 365 days of delivery (maOR 1.29, 95% CI 1.05-1.59).
CONCLUSION
CONCLUSIONS
Public insurance status does not serve as a barrier to either the preference or provision of effective postpartum contraception. Women desiring highly- or moderately effective methods of contraception should have these methods provided prior to hospital discharge to minimize barriers to method provision.
Identifiants
pubmed: 31908549
doi: 10.2147/OAJC.S231196
pii: 231196
pmc: PMC6927572
doi:
Types de publication
Journal Article
Langues
eng
Pagination
103-110Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR000440
Pays : United States
Informations de copyright
© 2019 Verbus et al.
Déclaration de conflit d'intérêts
Dr. Arora is funded by the Clinical and Translational Science Collaborative of Cleveland, KL2TR0002547 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical Research. This manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors report no other conflicts of interest.
Références
Am J Obstet Gynecol. 2015 Mar;212(3):312.e1-8
pubmed: 25218956
Contraception. 2017 May;95(5):452-455
pubmed: 28069491
Am J Obstet Gynecol. 2017 Jul;217(1):37-41
pubmed: 28390671
Obstet Gynecol. 2017 Sep;130(3):609-615
pubmed: 28796678
J Matern Fetal Neonatal Med. 2018 Nov;31(22):3014-3020
pubmed: 28764570
Am J Public Health. 2016 Jan;106(1):18-9
pubmed: 26562116
Contraception. 2008 Oct;78(4):271-83
pubmed: 18847574
Am J Obstet Gynecol. 2017 Jul;217(1):47.e1-47.e7
pubmed: 28263752
Am J Obstet Gynecol. 2015 Feb;212(2):171.e1-8
pubmed: 25093946
Womens Health Issues. 2001 Sep-Oct;11(5):427-35
pubmed: 11566285
Clin Obstet Gynecol. 2015 Jun;58(2):409-17
pubmed: 25811128
Obstet Gynecol. 2013 Dec;122(6):1214-21
pubmed: 24201685
Obstet Gynecol. 2017 Mar;129(3):408-415
pubmed: 28178044
Perspect Sex Reprod Health. 2011 Sep;43(3):181-7
pubmed: 21884386
Am J Obstet Gynecol. 2017 Jul;217(1):55.e1-55.e9
pubmed: 28257962
Obstet Gynecol. 2015 Jan;125(1):250-255
pubmed: 25560140
Demography. 2016 Oct;53(5):1399-1428
pubmed: 27624320
Am J Obstet Gynecol. 2017 May;216(5):504.e1-504.e10
pubmed: 28063910
Perspect Sex Reprod Health. 2010 Sep;42(3):176-85
pubmed: 20928956
Obstet Gynecol. 2012 Jul;120(1):212-5
pubmed: 22914423
Contraception. 2018 Jan;97(1):76-78
pubmed: 28887052
J Womens Health (Larchmt). 2018 May;27(5):676-683
pubmed: 29359987
Contraception. 2016 May;93(5):406-11
pubmed: 26738619
Am J Obstet Gynecol. 2014 Jun;210(6):526.e1-9
pubmed: 24495671
Am J Obstet Gynecol. 2015 Jul;213(1):46.e1-46.e6
pubmed: 25644443
NCHS Data Brief. 2015 Feb;(188):1-8
pubmed: 25714042
Contraception. 2019 Jan;99(1):32-35
pubmed: 30194927
Am J Obstet Gynecol. 2019 Jul;221(1):43.e1-43.e11
pubmed: 30885772
Am J Obstet Gynecol. 2013 Aug;209(2):103.e1-11
pubmed: 23524170
Womens Health Issues. 2015 Nov-Dec;25(6):622-7
pubmed: 26253826
Cad Saude Publica. 2013 Aug;29(8):1664-74
pubmed: 24005931
Contraception. 2018 May;97(5):399-404
pubmed: 29355492
Am J Obstet Gynecol. 2010 Oct;203(4):319.e1-8
pubmed: 20598282
Contraception. 2014 Jan;89(1):57-62
pubmed: 24237967
Contraception. 2018 Jun;97(6):559-564
pubmed: 29490290
Contraception. 2008 Jan;77(1):10-21
pubmed: 18082661
Obstet Gynecol. 2017 Aug;130(2):393-402
pubmed: 28697112
J Matern Fetal Neonatal Med. 2018 Mar;31(5):621-624
pubmed: 28395550